Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 595-602

  Harper, Jamie ^a,b,c   Skerry, Ciaran ^b,c   Davis, Stephanie L ^a,b,c   Tasneen, Rokeya ^b   Weir, Mariah ^a,b,c   Kramnik, Igor ^d   Bishai, William R ^b   Pomper, Martin G ^c   Nuermberger, Eric L ^b   Jain, Sanjay K ^a,b,c  

^a Center for Infection and Inflammation Imaging Research   (United States)

^b Center for Tuberculosis Research   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG GRANULOMA; MOUSE; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUBERCULOSIS; UPREGULATION;

EID: 84856301870     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir786     Document Type: Article

References (33)

1. Via LE, Lin PL, Ray SM, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008; 76:2333-40.
2. Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 2008; 29:542-51.
3. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97:8560-5. (Pubitemid 30639712)
4. Pan H, Yan BS, Rojas M, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005; 434:767-72. (Pubitemid 44739520)
5. Aly S, Wagner K, Keller C, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006; 210:298-305. (Pubitemid 44660508)
6. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity againstMycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 2008; 198:275-83. (Pubitemid 352019294)
7. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322:1392-5. (Pubitemid 352775253)
8. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-6. (Pubitemid 30435054)
9. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacteriumtuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49:2294-301. (Pubitemid 40734457)
10. Sun X, Niu G, Chan N, Shen B, Chen X. Tumor hypoxia imaging. Mol Imaging Biol 2010; 13(3):339-410.
11. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007; 43:4893-902. (Pubitemid 350015414)
12. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40:177-83. (Pubitemid 29044189)
13. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38:1155-60. (Pubitemid 27339632)
14. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y,Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001; 42:655-61. (Pubitemid 32298288)
15. Davis SL, Nuermberger EL, Um PK, et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009; 53:4879-84.
16. Davis SL, Be NA, Lamichhane G, et al. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS ONE 2009; 4:e6297.
17. Mangan J, Monahan I, Butcher P. Gene expression during host-pathogen interactions: approaches to bacterial mRNA extraction and labelling for microarray analysis. In: Functional microbial genomics. Wren B, Dorrell N, eds. Vol. 33. Burlington, MA: Elsevier, 2002: 137-51.
18. Larsen M. Some common methods in mycobacterial genetics. In: Jacobs W Jr, Hatfull G, eds. Molecular genetics of mycobacteria. Washington, DC: ASM Press, 2000: 137.
19. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52:1522-4. (Pubitemid 351522025)
20. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci USA 2001; 98:7534-9. (Pubitemid 32567983)
21. Voskuil MI, Visconti KC, Schoolnik GK. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 2004; 84:218-27. (Pubitemid 38857854)
22. Muttucumaru DG, Roberts G, Hinds J, Stabler RA, Parish T. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) 2004; 84:239-46. (Pubitemid 38857856)
23. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 2008; 3:e1502.
24. Rudin M, Rausch M, Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol Imaging Biol 2005; 7:5-13. (Pubitemid 41348870)
25. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003; 2:123-31. (Pubitemid 37361644)
26. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic responsea preliminary report. Int J Radiat Oncol Biol Phys 2003; 55: 1233-8. (Pubitemid 36338289)
27. Leyten EM, Lin MY, Franken KL, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006; 8:2052-60. (Pubitemid 44311602)
28. Timm J, Post FA, Bekker LG, et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci USA 2003; 100:14321-6. (Pubitemid 37499235)
29. Talaat AM, Lyons R, Howard ST, Johnston SA. The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci USA 2004; 101:4602-7. (Pubitemid 38437457)
30. Haapanen JH, Kass I, Gensini G, Middlebrook G. Studies on the gaseous content of tuberculous cavities. Am Rev Respir Dis 1959; 80:1-5.
31. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178: 989-93.
32. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:e344.
33. Prideaux B, Dartois V, Staab D, et al. High-sensitivity MALDIMRM-MS imaging of moxifloxacin distribution in tuberculosisinfected rabbit lungs and granulomatous lesions. Anal Chem 2011; 83:2112-8.